In the United States Military Cancer Institute-based phase I trial, the GP2 vaccine appeared to be well-tolerated and safe, as well as capable of triggering GP2-induced T-cell responses and delayed-type hypersensitivity responses when administered with GM-CSF in the patients with high-risk, LN– breast cancer [204]. The gene discussed is CSF2; the disease is breast carcinoma.